ABSTRACT
INTRODUCTION
There is increasing evidence for the role of bacterial infection in causing acute exacerbations of chronic obstructive pulmonary disease (AECOPD), particularly in those patients with chronic bronchitis (CB) who present with all three cardinal symptoms defined by Anthonisen et al (1) .
The frequency of exacerbations adversely affects disease progression and overall health status (2) (3) (4) . Studies involving sputum analysis, bronchoscopic sampling, molecular epidemiology of bacterial strains and immunology have linked the presence of bacterial infection with AECOPD and bacterial eradication with recovery (5-10). Chronic inflammation has been associated with bacterial persistence, and the number of bacteria present in the airway with disease progression (11-14).
It is therefore surprising that the benefits of antibiotic treatment of exacerbations have not been more clearly defined (15, 16). Most guidelines have used the Anthonisen criteria to decide when an antibiotic should be prescribed, but little evidence of efficacy differences between antibiotics has been gathered (1, 15) . In the context of a marked increase in the prevalence of bacterial strains resistant to antibiotics such as amoxicillin, tetracycline and erythromycin, the recently published Canadian guidelines have attempted to define at risk patients who might benefit from newly developed antibiotics that are active against resistant strains (15,17, 18).
In a meta-analysis of AECOPD placebo-controlled trials, there was a small but significant benefit from antibiotic treatment on overall recovery and change in peak-flow (19). However most antibiotic trials have compared one antibiotic to another. These trials were usually evaluating a short-term outcome, defined as improvement in signs and symptoms sufficient so that further antibiotic prescription is not necessary. They compared antibiotic regimens in 4 heterogeneous populations, with poorly defined disease severity and most studies were underpowered to demonstrate superiority (15). In that context, they have almost all shown clinical equivalence, even when one antibiotic has shown superior bacteriological eradication (15, 20) .
This discrepancy could have several explanations. Most airway infections causing AECOPD are superficial, although mucosal invasion can occur, and efficient host defenses lead to high spontaneous recovery rates (1, 21) . The opportunity to show differences between antibiotics may be greater in patients with more severe disease, or with risk factors for poor outcome (15, 22) . Patients with persistent bacterial infection due to ineffective antibiotic treatment might improve by reducing bacterial numbers, but their recovery may be incomplete and they could have a more rapid relapse (11). Consequently, long-term follow up might reveal differences in efficacy between antibiotics.
The MOSAIC study was designed to meet those shortcomings (22). This large trial compared the short and long-term outcomes of antibiotic treatments in a population with a history of heavy smoking and significant lung function impairment. Moxifloxacin showed clinical equivalence to standard therapy for clinical success (the primary outcome measure), and achieved superior clinical cure rates, defined as return to baseline health status, and significantly higher bacteriologic eradication rates over standard therapy. Fewer patients required additional antimicrobials in the weeks following the exacerbation and the time to next AECB was significantly longer after treatment with moxifloxacin. In the analysis of a composite endpoint comprising treatment failure, new exacerbation, or any further antibiotic for lower respiratory tract illness, moxifloxacin was shown to be statistically significantly superior for up to 5 months of follow-up.
The superiority of moxifloxacin demonstrated in these secondary outcomes could be due to more successful bacteriological eradication, which led to resolution of bronchial inflammation, a complete return to baseline symptoms, fewer rapid relapses requiring antibiotic treatment, and a longer time to next exacerbation. We have now investigated which clinical features were associated with the short and long-term treatment outcomes. We have then looked at the results of antibiotic treatments in these sub-groups to see whether the differences between moxifloxacin and comparator antibiotics were increased or reduced.
METHODS

Design:
This was a prospective, randomized, double-blind study which design and primary outcomes were previously reported (22). Outpatients aged <45 years with documented chronic bronchitis were eligible for enrolment during an AECB-free period if they had a history of cigarette smoking of at least 20 pack years, two or more documented AECB in the previous year, and FEV 1 < 85% of predicted value at the enrolment visit. Patients then presenting with an Anthonisen type 1 AECB were randomized to receive either treatment with moxifloxacin (400 mg once daily for five days), or one of the following comparators chosen by the investigators between amoxicillin (500 mg three times daily for 7 days), clarithromycin (500 mg twice daily for 7 days), or cefuroxime-axetil (250 mg twice daily for 7 days) . no steroid use at randomization or no increase in long-term steroid dosage; long-term inhaled steroids administered for more than 2 months prior to randomization and/or systemic steroids started at randomization or increased dosage at randomization if previously administered were classified as steroid administration. Bronchodilator administration was defined as the use of any bronchodilator type at acute phase, i.e. between randomization and 7-10 days after end of treatment: short-acting and long-acting, beta agonist and/or anticholinergic.
Analysis:
The association between each individual prognostic factor and clinical outcomes (clinical cure, clinical success, and composite endpoint) was tested by Chi square tests. The independent prognostic contributions of individual factors to the clinical outcomes were then tested by multivariate stepwise logistic regression analyses for clinical cure and clinical success, respectively. Because the composite endpoint was the time-dependent variable, the multivariate analysis used a stepwise Cox regression model. The threshold for statistical significance was p=0.05. Interactions between treatment and prognostic factors were then tested for the factors that proved significant in the multivariate analyses, using a threshold of p=0.10. When the interaction test was inferior to that threshold, the between-treatment difference at each level was described. The statistical software packages SAS Windows V6.12 and 8.2 were used.
Ethics:
The study protocol was approved by ethics committees, and patients provided their written informed consent. 
RESULTS
The full description of patients studied (n=730) and their randomization is given in the on line supplement (Table 5 ). The mean age (SD) was 63.2 (9.8), 42.3% had FEV 1 <50%, 27.7% had >4 exacerbations in the last year and the mean (SD) years since diagnosis of chronic bronchitis was 12.5 (0.8). There was no significant difference between these values in the randomization to the two arms of the study Clinical cure: the factors identified in the univariate analysis were antibiotic treatment, steroid use, cardiopulmonary diseases, FEV 1 , number of previous AECB and elapsed time from previous AECB. All other factors were not statistically significant (Table 1) .
group.bmj.com on April 1, 2017 -Published by http://thorax.bmj.com/ Downloaded from 
The full analysis including non significant factors is shown in the on line supplement Table 6 .
When a multivariate logistic model was applied, Moxifloxacin was independently associated with a higher clinical cure rate than comparator while comorbid cardiopulmonary disease, FEV 1 <50% predicted and >4 AECB in the previous year had a detrimental effect on outcome (table   2) . Long-term outcome: in univariate analyses, the factors that significantly impacted the occurrence of the composite event were >4 AECB in previous year and use of acute bronchodilators use (Table 3) . 
The full analysis including non-significant risk factors is shown in the on line supplement Table 8 .
In the multivariate model, antibiotic treatment, age >65 years, FEV 1 <50% predicted, >4 AECB in the previous year, and acute bronchodilator use had a statistically significant effect on longterm outcome (Table 4) . The findings of this post hoc analysis of the MOSAIC study are similar to the published evidence that severity of airflow destruction, co-existing cardiopulmonary disease and the frequency of previous exacerbations were risk-factors for poorer short-term outcomes (23-30).
group
The number of previous AECB appeared to have a more powerful influence than age and duration of the disease, probably because repeated exacerbations are linked to disease progression. Whilst having cardiopulmonary disease as a co-morbid illness was a potent negative predictor of short-term outcome, BMI equal to or below 30kg/M 2 and diabetes did not play a role.
Current smoking habit has previously been associated with lower airway bacterial colonization but in this study it did not impact either clinical cure or clinical success (31, 32). This discrepancy could be due to the homogeneity of the study population and the lack of a reference group of non smokers. In fact, patients enrolled in the MOSAIC study were selected to increase the likelihood that bacterial infection was the cause of their exacerbation. They had to have the three cardinal symptoms of an Anthonisen type one exacerbation including increased breathlessness and sputum production, purulent sputum, and had a long history of chronic bronchitis due to cigarette smoking (1, 22) . Similarly, FEV 1 <50% predicted and acute use of bronchodilators appeared to be independent negative predictors of long-term outcome, while the use of corticosteroids had no predictive value there. Clinical interpretation of the findings of this post hoc analysis must be interpreted with caution given the exploratory nature of this analysis and the fact that corticosteroids and bronchodilatators were not randomized in the trial. In the context of the MOSAIC study, the use of bronchodilators and/or corticosteroids, together with impaired FEV1, identified a patient subgroup at higher risk of failure, and further research will be needed to find out which of these three parameters has the best prognostic value in clinical practice. The data also suggest that use of bronchodilators, most likely to treat wheezing, might be a direct or indirect marker of disease severity which influences the short and long-term outcomes of antibiotic treatment, a hypothesis that could only be further tested in a randomized factorial design.
Another study design issue will require consideration in the future. The features of the exacerbation leading to antibiotic randomisation are defined by the Anthonisen type 1 criteria to capture a group of patients judged most likely to benefit from antibiotics (1). In the MOSAIC and the stratification of the randomisation on corticosteroids, between-group differences could still be confounded by underlying factors related to the medical history, the severity of the disease, and to the use of concomitant medications. It suggests that future clinical trials of antibiotic therapies in AECB systematically take these factors into account either a priori (at randomisation) or a posteriori (statistical analysis) in order to increase the sensitivity of studies to detect differences between antibiotic regimens.
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